Construction and in vitro testing of a novel Fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor Xa-dependent manner

Journal of Cardiovascular Pharmacology

Volumn 42, Issue 2, 2003, Pages 237-244

  Peter, Karlheinz ^a   Gupta, Amitabh ^b   Nordt, Thomas ^a   Bauer, Simone ^a   Runge, Marschall S ^c   Bode, Christoph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Factor Xa; Fibrin; Fusion protein; Hirudin; Thrombin; Thrombus

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; DNA; FIBRIN; HIRUDIN; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; THROMBIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CHEMICAL INTERACTION; FIBRINOLYSIS; GENOME; MOLECULAR SIZE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; THROMBOSIS; THROMBUS;

ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ANTITHROMBINS; CELL LINE; FACTOR XA; FIBRIN; HIRUDINS; HYBRIDOMAS; IMMUNOGLOBULIN FAB FRAGMENTS; PLASMIDS; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; THROMBIN; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 0042804860     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200308000-00013     Document Type: Article

References (38)

1. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion. Am J Cardiol. 1995;75:12B-17B.
2. Meyer BJ, Fernandez-Ortiz A, Mailhac A, et al. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation. 1994; 90:2474-2480.
3. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation. 1994;89:1557-1566.
4. Cannon CP, Braunwald E. Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty. J Am Coll Cardiol. 1995;25: 30S-37S.
5. Loscalzo J. Thrombin inhibitors in fibrinolysis. A Hobson's choice of alternatives. Circulation. 1996;94:863-865.
6. Haskel EJ, Prager NA, Sobel BE, et al. Relative efficiency of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation. 1991;83:1048-1056.
7. White HD, Aylward BM, Frey MJ, et al. on behalf of the HERO trial investigators. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation. 1997;96:2155-2161.
8. Bode C, Hudelmayer M, Mehwald P, et al. Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin. Circulation. 1994;90:1956-1963.
9. Bode C, Hanson SR, Schmedtje JF, et al. Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting. Circulation. 1997;95:800-804.
10. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science. 1983; 222:1129-1132.
11. Bode C, Matsueda GR, Hui KY, et al. Antibody-directed urokinase: a specific fibrinolytic agent. Science. 1985;229:765-767.
12. Bode C, Runge MS, Schönermark S, et al. Conjugation to antifibrin Fab′ enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Circulation. 1990;81:1974-1980.
13. Runge MS, Quertermous T, Zavodny PJ, et al. Recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Natl Acad Sci U S A. 1991;88: 10337-10341.
14. Lazar JB, Winant RC, Johnson PH. Hirudin: amino-terminal residues play a major role in the interaction with thrombin. J Biol Chem. 1991;266: 685-688.
15. Eisenberg PR, Siegel JE, Abendschein DR, et al. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest. 1993;91:1877-1883.
16. McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vasc Biol. 1996;16: 1285-1291.
17. Schnee JM, Runge MS, Matsueda GR, et al. Construction and expression of a recombinant antibody-targeted plasminogen activator. Proc Natl Acad Sci U S A. 1987;84:6904-6908.
18. Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol. 2001;21:1094-1096.
19. Meyer BJ, Badimon JJ, Chesebro JH, et al. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin. Comparison with heparin and aspirin. Circulation. 1998;97:681-685.
20. Heras M, Chesebro JH, Webster MB, et al. Hirudin, heparin, and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet mediated thrombosis. Circulation. 1990;82:1476-1484.
21. Chesebro JH. Direct thrombin inhibition superior to heparin during and after thrombo-lysis. Circulation. 1997;96:2118-2120.
22. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86: 385-391.
23. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by anti-thrombin-independent inhibitors. Circulation. 1998;97:544-552.
24. Rigel DF, Olson RW, Lappe RW. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombolysis. Circ Res. 1993;72:1091-1102.
25. Mruk JS, Zoldhelyi P, Webster MWI, et al. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effect of recombinant hirudin, heparin, and aspirin. Circulation. 1996;93: 792-799.
26. Theroux P, Perez-Villa F, Walters D, et al. Randomized double-blind comparison of two dosis of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation. 1995;91:2132-2139.
27. Metz BK, White HD, Granger CB, et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. J Am Coll Cardiol. 1998;31:1493-1498.
28. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study. Circulation. 1997;96:769-777.
29. Organisation to Assess Strategies for Ischemic Syndromes. (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: a randomised trial. Lancet. 1999;353:429-438.
30. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 2002;359: 294-302.
31. Mehta SR, Eikelboom JW, Rupprecht HJ, et al. Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. Eur Heart J. 2002; 23:217-223.
32. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
33. Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
34. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. Circulation. 1994;90:1638-1642.
35. Antman EM. The search for replacements for unfractionated heparin. Circulation. 2001;103:2310-2314.
36. Holvoet P, Stassen JM, Hashimoto Y, et al. Binding properties of monoclonal antibodies against human fragment D-dimer of cross-linked fibrin to human plasma clots in an in vivo model in rabbits. Thromb Haemost. 1989;61:307-313.
37. Holvoet P, Laroche Y, Lijnen HR, et al. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-Dimer-specific antibody and a truncated single chain urokinase. J Biol Chem. 1991;266:19717-19724.
38. Peter K, Graeber J, Kipriyanov S, et al. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation. 2000;101:1158-1164.